These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 26259876

  • 1. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y, Matsushima Y, Shiroiwa T, Chiba K, Nakanishi Y, Kurokawa T, Urushihara H.
    Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
    [Abstract] [Full Text] [Related]

  • 2. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T, Boland A, Bagust A, Oyee J, Hockenhull J, Dundar Y, Dickson R, Ramani VS, Proudlove C.
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [Abstract] [Full Text] [Related]

  • 3. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L.
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.
    Arrieta O, Anaya P, Morales-Oyarvide V, Ramírez-Tirado LA, Polanco AC.
    Eur J Health Econ; 2016 Sep; 17(7):855-63. PubMed ID: 26338546
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lu S, Ye M, Ding L, Tan F, Fu J, Wu B.
    Oncotarget; 2017 Feb 07; 8(6):9996-10006. PubMed ID: 28036283
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
    Lee VW, Schwander B, Lee VH.
    Hong Kong Med J; 2014 Jun 07; 20(3):178-86. PubMed ID: 24281768
    [Abstract] [Full Text] [Related]

  • 7. Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
    Zhu J, Li T, Wang X, Ye M, Cai J, Xu Y, Wu B.
    BMC Cancer; 2013 Jan 29; 13():39. PubMed ID: 23360224
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
    Cai H, Zhang L, Li N, Chen S, Zheng B, Yang J, Weng L, Liu MB.
    Clin Ther; 2019 Feb 29; 41(2):280-290. PubMed ID: 30639208
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
    Li WQ, Li LY, Chai J, Cui JW.
    Cancer Med; 2021 Mar 29; 10(6):1964-1974. PubMed ID: 33626238
    [Abstract] [Full Text] [Related]

  • 10. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).
    Thongprasert S, Duffield E, Saijo N, Wu YL, Yang JC, Chu DT, Liao M, Chen YM, Kuo HP, Negoro S, Lam KC, Armour A, Magill P, Fukuoka M.
    J Thorac Oncol; 2011 Nov 29; 6(11):1872-80. PubMed ID: 22011650
    [Abstract] [Full Text] [Related]

  • 11. Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
    Lim EA, Lee H, Bae E, Lim J, Shin YK, Choi SE.
    PLoS One; 2016 Nov 29; 11(8):e0160155. PubMed ID: 27483001
    [Abstract] [Full Text] [Related]

  • 12. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
    You JHS, Cho WCS, Ming WK, Li YC, Kwan CK, Au KH, Au JS.
    PLoS One; 2021 Nov 29; 16(3):e0247860. PubMed ID: 33647045
    [Abstract] [Full Text] [Related]

  • 13. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.
    Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL.
    Value Health; 2009 Nov 29; 12(1):20-7. PubMed ID: 18647257
    [Abstract] [Full Text] [Related]

  • 14. A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease.
    Mariano C, Bosdet I, Karsan A, Ionescu D, Murray N, Laskin JJ, Zhai Y, Melosky B, Sun S, Ho C.
    Lung Cancer; 2014 Jan 29; 83(1):73-7. PubMed ID: 24192511
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung.
    Handorf EA, McElligott S, Vachani A, Langer CJ, Bristol Demeter M, Armstrong K, Asch DA.
    J Oncol Pract; 2012 Sep 29; 8(5):267-74. PubMed ID: 23277762
    [Abstract] [Full Text] [Related]

  • 16. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
    Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT, Yang JJ, Rukazenkov Y.
    Lung Cancer; 2013 Aug 29; 81(2):280-7. PubMed ID: 23540718
    [Abstract] [Full Text] [Related]

  • 17. [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
    Protsenko SA, Rudakova AV.
    Vopr Onkol; 2015 Aug 29; 61(4):676-80. PubMed ID: 26571844
    [Abstract] [Full Text] [Related]

  • 18. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS.
    Lancet Oncol; 2015 Aug 29; 16(8):990-8. PubMed ID: 26159065
    [Abstract] [Full Text] [Related]

  • 19. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose Y, Yang JJ, Mok TS, Young H, Haddad V, Rukazenkov Y, Fukuoka M.
    Lung Cancer; 2017 Feb 29; 104():119-125. PubMed ID: 28212993
    [Abstract] [Full Text] [Related]

  • 20. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
    Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T, Fukuoka M.
    J Thorac Oncol; 2012 Jan 29; 7(1):115-21. PubMed ID: 21900837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.